The WGNV Chair and Co-Chairs are responsible for leading, guiding and coordinating the Core Group, the WGNV, and subgroups and task forces.
The WGNV Core Group guides the strategic direction and programs of the WGNV. It facilitates and accelerates decision making, identifies priority areas of work, and is responsible for ensuring the effectiveness of the WGNV. The Core Group is constituency-based, representing the major stakeholder groups involved in TB vaccine research and development.
The WGNV Secretariat works in close collaboration with the Chair, Co-Chairs and Core Group to develop and implement the WGNV strategy and work plans, facilitate effective communications, and coordinate the WGNV and its programs.
WGNV membership is open to anyone with an interest in TB vaccine research and development. WGNV members have the opportunity to participate in WGNV subgroups and contribute to WGNV initiatives, in collaboraiton with WGNV leadership.
The WGNV is hosted by IAVI
Chair & Co-Chairs
Core Group Members (by constituency)
Academic Institutions: Richard G. White, London School of Hygiene and Tropical Medicine (UK)
Affected Communities: Rhea Lobo, Bolo Didi (Denmark and India)
Clinical Trial Sites: Michele Tameris, South African Tuberculosis Vaccine Initiative (South Africa)
Developed Country NGOs/Advocacy Networks: Shaun Palmer, TB Vaccine Advocacy Roadmap (TB Vax ARM) (Netherlands)
Early Career Researchers: Puck Pelzer, KNCV Tuberculosis Foundation (Netherlands); Paul Ogongo, University of California San Francisco (USA)
Funders: Ann Ginsberg, Bill & Melinda Gates Foundation (USA)
Global TB Vaccine Partnership: Michael Makanga (Netherlands)
IAVI: Lewis Schrager (USA)
Public Sector: Katrin Eichelberg, National Institute of Allergy and Infectious Diseases/National Institutes of Health (USA)
Private Sector/Industry: Eileen Foy, Vir Biotechnology (USA)
World Health Organization: Brigitte Giersing, Vaccine and Product Delivery Research, World Health Organization (Switzerland)
Mbali Mkohnza, Intern (South Africa)